Real-World Treatment Patterns and Outcomes of Zanubrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at University of California Academic Health Centers: A Retrospective Cohort Study.
Zanubrutinib kept patients on treatment longer than acalabrutinib in real-world blood cancer care, with similar survival outcomes between the two drugs.
This retrospective cohort study examined real-world outcomes with zanubrutinib versus acalabrutinib. Zanubrutinib was associated with longer treatment persistence, while time to next treatment and overall survival did not differ significantly.
What the study was
- Study design
- Retrospective cohort study
- Population
- 481 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma
- Sample size
- 481
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Oncology and therapy
Why it surfaced
Retained as a standard-priority retrospective cohort study after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.